Litigation Details for Allergan, Inc. v. Sandoz, Inc. (E.D. Tex. 2012)

« Back to Dashboard

Allergan, Inc. v. Sandoz, Inc. (E.D. Tex. 2012)

Docket		Date Filed	2012-04-13
Court	District Court, E.D. Texas	Date Terminated	2017-01-09
Cause	35:271 Patent Infringement	Assigned To	James Rodney Gilstrap
Jury Demand	Defendant	Referred To
Parties	APOTEX CORP
Patents	7,030,149; 7,320,976; 7,323,463; 7,642,258; 8,133,890; 8,354,409; 8,748,425
Attorneys	Jessica Anne Roberts
Firms	Siebman Burg Phillips & Smith, LLP-Marshall
Link to Docket	External link to docket

Details for Allergan, Inc. v. Sandoz, Inc. (E.D. Tex. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-04-13				External link to document

Allergan v. Sandoz, Inc. Case 2:12-cv-00207: Litigation Summary and Patent Analysis

Last updated: November 5, 2026

Allergan, Inc. v. Sandoz, Inc., No. 2:12-cv-00207, was a Hatch-Waxman dispute over Sandoz’s proposed generic version of Lumigan 0.01%, Allergan’s bimatoprost ophthalmic solution for glaucoma and ocular hypertension. The dispute centered on U.S. Patent No. 7,851,504, covering a low-concentration bimatoprost formulation. The district court ruled for Allergan, and the Federal Circuit affirmed the key infringement and validity findings in 2015. The decision preserved Allergan’s patent protection against the specific Sandoz ANDA product during the remaining patent term. (Allergan, Inc. v. Sandoz, Inc., 2015)

What drug and formulation were at issue in Allergan v. Sandoz?

The product was Lumigan 0.01%, an ophthalmic solution containing bimatoprost.

Product profile

Item	Detail
Brand	Lumigan 0.01%
Active ingredient	Bimatoprost
Dosage form	Topical ophthalmic solution
Primary uses	Glaucoma and ocular hypertension
Reference company	Allergan, Inc.
Regulatory pathway	Abbreviated New Drug Application, or ANDA
Challenging company	Sandoz Inc.
Case	No. 2:12-cv-00207, U.S. District Court for the Eastern District of Texas

Lumigan 0.01% was developed as a lower-concentration formulation than Allergan’s earlier Lumigan 0.03% product. The formulation was designed to maintain pressure-lowering efficacy while reducing treatment-related side effects, including conjunctival hyperemia.

What patents protected Lumigan 0.01%?

The principal patent addressed in the Federal Circuit appeal was U.S. Patent No. 7,851,504, generally directed to ophthalmic bimatoprost formulations.

U.S. Patent No. 7,851,504

Field	Information
Patent number	7,851,504
Patent holder	Allergan, Inc.
Technical subject	Low-concentration bimatoprost ophthalmic formulation
Relevant concentration	Approximately 0.01% bimatoprost
Filing and priority history	Based on Allergan’s bimatoprost formulation development work
Litigation role	Asserted against Sandoz’s ANDA product
Federal Circuit decision	2015

The asserted claims required a formulation with specific compositional and concentration limitations. The dispute was therefore narrower than a broad monopoly over bimatoprost. It concerned whether Sandoz’s proposed product fell within the patented low-dose formulation and whether the claimed formulation would have been obvious in view of earlier bimatoprost products and formulation knowledge.

Allergan also maintained additional patent protection around Lumigan and ophthalmic formulations through related patents and continuation activity. The Federal Circuit decision, however, is principally associated with the ’504 patent.

What were the legal claims in the litigation?

Allergan brought the action after Sandoz submitted an ANDA containing a Paragraph IV certification challenging the asserted patent.

Allergan’s claims

Allergan alleged that:

1. Sandoz’s proposed generic product would infringe the ’504 patent.
2. Sandoz’s Paragraph IV certification created a statutory act of infringement under the Hatch-Waxman framework.
3. The asserted claims were valid and enforceable.
4. The lower-concentration bimatoprost formulation was not an obvious modification of the earlier Lumigan 0.03% product.

Sandoz’s defenses

Sandoz challenged the patent on conventional ANDA-litigation grounds:

• Non-infringement.
• Anticipation and obviousness.
• Claim-construction limitations.
• Lack of patentable distinction over prior bimatoprost formulations.
• Arguments that reducing the concentration did not produce a non-obvious technical advance.

The case did not involve biologic interchangeability, biosimilar approval, or a biologics license application. It was a small-molecule ANDA case under 21 U.S.C. § 355(j).

What did the district court decide?

The Eastern District of Texas ruled in Allergan’s favor after trial. The court found that the asserted claims were infringed and rejected Sandoz’s invalidity arguments.

The principal factual issue was whether the claimed 0.01% bimatoprost formulation represented a predictable optimization of the earlier 0.03% formulation. The court credited Allergan’s evidence that the lower concentration produced clinically meaningful benefits without sacrificing efficacy. The evidence included formulation development data, clinical results, and unexpected reduction in adverse effects.

The ruling prevented Sandoz from obtaining an immediately marketable generic launch based on the ANDA product while the ’504 patent remained enforceable.

What did the Federal Circuit decide?

The Federal Circuit affirmed the district court’s judgment in 2015. The appellate decision addressed both infringement and obviousness.

Validity

The Federal Circuit rejected Sandoz’s argument that the claimed formulation was an obvious adjustment of the prior Lumigan formulation. The court accepted the district court’s assessment that the claimed lower concentration produced unexpected results relevant to patentability.

The decision applied the established obviousness framework under 35 U.S.C. § 103. The existence of a reason to modify the prior product was not enough. The record also had to support a reasonable expectation that the modification would achieve the claimed combination of efficacy and reduced side effects.

Infringement

The Federal Circuit upheld the determination that Sandoz’s proposed product met the relevant limitations of the asserted claims. The ANDA and product specifications were sufficient to establish infringement in the Hatch-Waxman context.

Commercial effect

The appellate decision maintained the district court judgment against Sandoz. It did not create a broad rule covering every bimatoprost product. Its practical effect was specific to the asserted formulation claims and Sandoz’s proposed ANDA product.

When did the patent protection for Lumigan 0.01% expire?

The ’504 patent was associated with a statutory patent term extending into the mid-2020s. The relevant term was tied to the earliest applicable U.S. nonprovisional priority date, subject to patent-term adjustment and any terminal-disclaimer or maintenance-fee issues reflected in the official patent record.

The case itself did not establish a permanent barrier to generic entry. It confirmed the patent’s enforceability for the remaining term at the time of judgment. Once the relevant patent protection expired, the litigation judgment no longer independently prevented FDA approval or commercial launch of an otherwise approvable generic product.

The FDA Orange Book must be consulted for the operative listed patents, patent-use codes, and any current delisting or expiration status. The Orange Book listing is distinct from the judicial finding that the ’504 patent was valid and infringed. (U.S. Food and Drug Administration, 2025)

What was the Paragraph IV challenge and 30-month stay effect?

Sandoz’s ANDA included a Paragraph IV certification asserting that the relevant patent was invalid, unenforceable, or not infringed. Allergan’s infringement action triggered the Hatch-Waxman 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and court orders.

The litigation therefore had two linked effects:

1. It gave Allergan an automatic regulatory stay against approval of the challenged ANDA for the statutory period.
2. The final infringement judgment provided a patent-based basis to delay commercial launch beyond the stay while the patent remained in force.

The Federal Circuit’s affirmance strengthened Allergan’s position by removing the principal appellate challenge to the patent judgment.

Did the case involve formulation patents or method-of-use patents?

The case was primarily a formulation-patent dispute.

Formulation protection

The asserted protection focused on:

• Bimatoprost concentration.
• Ophthalmic solution composition.
• Formulation characteristics associated with tolerability and efficacy.
• The relationship between the low active-ingredient concentration and the resulting clinical profile.

Method-of-use protection

The dispute was not principally resolved through a method-of-use patent. Lumigan products can also be associated with patented indications and FDA-approved uses, but the Federal Circuit decision in this matter is primarily cited for the formulation patent and the obviousness analysis surrounding the 0.01% bimatoprost composition.

For generic-entry analysis, a formulation patent can be more difficult to design around than a use-only patent when the ANDA product necessarily contains the claimed composition. A method-of-use patent may permit a skinny-label strategy under 21 U.S.C. § 355(j)(2)(A)(viii). A formulation patent generally creates a direct product-infringement risk if the proposed generic contains the claimed ingredients and concentrations.

What was the litigation timeline?

Date	Event
2012	Allergan filed the Eastern District of Texas action after Sandoz submitted its ANDA and Paragraph IV certification
2012-2014	Claim-construction, discovery, and trial proceedings
Pre-2015	District court found infringement and rejected Sandoz’s invalidity defenses
2015	Federal Circuit affirmed the principal judgment
Mid-2020s	Relevant patent protection reached the end of its ordinary commercial blocking period

The appeal is reported at 796 F.3d 1293. The Federal Circuit opinion is the primary public authority for the case’s patent-validity and infringement holdings.

Was there a settlement or licensing agreement?

The reported appellate decision reflects an adjudicated judgment rather than a publicly disclosed settlement resolving the appeal. No material license granted to Sandoz is identified in the Federal Circuit opinion.

Any confidential commercial resolution, launch license, or later agreement would not alter the Federal Circuit’s reported holding unless incorporated into a subsequent court order or regulatory record.

Which companies challenged Allergan’s Lumigan exclusivity?

Sandoz was the defendant in this action. Other generic companies pursued or could pursue separate bimatoprost ANDA strategies, but those proceedings must be analyzed independently because:

• Different ANDA formulations may not infringe the same claims.
• Paragraph IV certifications may target different patents.
• FDA approval dates can differ.
• Settlements can create different licensed-entry dates.
• A later generic may rely on patent expiry rather than prevail on invalidity.

The Allergan v. Sandoz result should not be treated as a judgment against all possible bimatoprost formulations.

How strong was Allergan’s patent estate?

The estate was strong against the specific Sandoz formulation at issue but narrower than a product-wide exclusivity claim.

Strengths

• The patent covered a commercially important low-concentration formulation.
• The formulation had clinical evidence supporting reduced adverse effects.
• The district court credited unexpected results.
• The Federal Circuit affirmed the validity and infringement findings.
• The claimed composition created direct ANDA infringement exposure.

Limitations

• The patent did not prevent every bimatoprost formulation.
• The protection was limited by the claim language.
• Patent blocking power ended with expiration.
• Competing formulations could potentially avoid specific concentration or excipient limitations.
• The judgment did not establish that all generic bimatoprost products infringed.

What generic launch risks existed after the decision?

Sandoz faced a high launch risk before patent expiry because the appellate affirmance left the infringement judgment intact. A commercial launch during the enforceable patent term could have exposed Sandoz to injunction, damages, or other patent remedies.

After patent expiry, the risk profile shifted:

• Patent-infringement risk declined sharply for products outside any surviving patents.
• FDA approval remained dependent on ANDA completeness and bioequivalence.
• Other Orange Book-listed patents could still affect approval or labeling.
• Manufacturing changes could create new formulation or process patent exposure.
• State and federal substitution rules could affect the timing and scale of commercial uptake.

The principal barrier in this case was not manufacturing know-how alone. It was the combination of a protected formulation, clinical support for non-obviousness, and the Hatch-Waxman litigation mechanism.

What was the commercial and revenue exposure?

The case involved a commercially significant glaucoma product, but the reported opinions do not quantify Allergan’s revenue exposure from the Sandoz ANDA or identify a specific lost-sales calculation.

The economic stakes included:

• Continued branded sales of Lumigan 0.01%.
• Preservation of price and market share before generic entry.
• Potential erosion from generic substitution after patent expiry.
• The value of Allergan’s formulation-development investment.
• Sandoz’s opportunity to enter the U.S. ophthalmic glaucoma market.

The judgment protected the branded product during the relevant patent term but did not eliminate eventual generic erosion.

Key Takeaways

• Allergan sued Sandoz over a Paragraph IV ANDA for generic Lumigan 0.01%.
• The central patent was U.S. Patent No. 7,851,504.
• The patent covered a low-concentration bimatoprost ophthalmic formulation.
• The district court found infringement and rejected Sandoz’s invalidity defenses.
• The Federal Circuit affirmed the principal judgment in 2015.
• The decision relied heavily on unexpected clinical and formulation results.
• The case was a small-molecule ANDA dispute, not a biosimilar case.
• The ruling protected Allergan against the specific Sandoz product during the remaining patent term.
• The decision did not prevent all alternative bimatoprost formulations.
• Commercial exclusivity ultimately depended on patent expiration, Orange Book status, and any other surviving patent rights.

FAQs About Allergan v. Sandoz, No. 2:12-cv-00207

What was the drug in Allergan v. Sandoz?

The drug was Lumigan 0.01%, an ophthalmic bimatoprost solution used to lower intraocular pressure in glaucoma and ocular hypertension.

What patent did Allergan assert against Sandoz?

The principal asserted patent was U.S. Patent No. 7,851,504, directed to a low-concentration bimatoprost ophthalmic formulation.

Did Sandoz win on obviousness?

No. The district court rejected Sandoz’s obviousness defense, and the Federal Circuit affirmed the key judgment.

Did Allergan obtain a permanent injunction against all bimatoprost generics?

No. The judgment applied to the accused Sandoz ANDA product and the enforceable patent claims. It did not automatically cover every bimatoprost generic or alternative formulation.

Is this case relevant to biosimilar litigation?

No. Bimatoprost is a small-molecule drug approved through the ANDA pathway. The case does not involve a biosimilar, reference biologic, or interchangeable-biologic designation.

References

Allergan, Inc. v. Sandoz, Inc., 796 F.3d 1293 (Fed. Cir. 2015).

U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

U.S. Patent No. 7,851,504. (2010). Ophthalmic bimatoprost formulations. United States Patent and Trademark Office. https://patents.google.com/patent/US7851504B2/en

U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda